Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chromagen-3M agreement targets diagnostics

This article was originally published in Clinica

Executive Summary

Chromagen, a US development-stage IVD company based in San Diego, has formalised its technology development agreement with 3M which has already resulted in solid phase extraction chemistries. Under the agreement, Chromagen has worldwide, exclusive rights to the application of the technology in infectious disease diagnostics. The two companies have set up a joint committee to direct development of the technology and promote business opportunities.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel